- About Us
- Career Center
- Nano-Social Network
- Nano Consulting
- My Account
Starpharma (ASX:SPL, OTCQX: SPHRY), through its US subsidiary company Dendritic
Nanotechnologies Inc (DNT), has found that DNT's Priostar(TM) dendrimer
technology can be used to amplify the signal and increase the duration of
the signal (photostability) of existing products in the multi-billion
dollar fluorescent reagents market. The company has filed a patent for the
discovery through DNT.
Fluorescent reagents are used extensively in laboratories for high-
throughput screening, diagnostic immunoassays, microarrays, fluorescence
microscopy, genomics and proteomics. Strong signals and photostability are
extremely important properties as they increase the sensitivity of
detection methods and facilitate measurement of the signal, respectively.
Increased sensitivity is needed to study disease markers that are
present at very low levels -- often below those detectable with current
Using its Priostar(TM) technology, DNT has created dye-dendrimer
complexes from various commercial dyes that show significantly enhanced
fluorescent (greater than 10 fold) and photostability (greater than 4
fold), in addition to improved solubility in water.
Preliminary testing has shown that the enhanced properties of
Priostar(TM) dendrimer-dye complexes are retained after attachment to an
antibody, an integral component for many of the applications of fluorescent
"Market feedback indicates that the scientific community and industry
users of these products will highly value the availability of reagents with
increased sensitivity and photostability," said Dr. Lori Reyna, director of
life sciences at DNT. Scientists are always keen to increase the
sensitivity of detection and quantitation methods."
DNT will partner with established leaders in the diagnostic and
research reagent industries through licensing and supply agreements. The
initial commercialization target will be the research reagent and in vitro
diagnostic markets. DNT is currently in preliminary commercialization
discussions with the market leaders in the area of fluorescence reagents.
Starpharma Holdings Limited (ASX:SPL, OTCQX:SPHRY) is a world leader in
the development of dendrimer nanotechnology for pharmaceutical,
life-science and other applications. SPL is principally composed of two
operating companies, Starpharma Pty Ltd in Melbourne, Australia and
Dendritic Nanotechnologies, Inc in Michigan, USA.
For more information, please click here
Tel: +61 2 9237 2800
Mob: +61 417 382 391
Dr Jackie Fairley
Chief Executive Officer Starpharma Holdings Ltd
+61 3 8532 2704
Dr Robert Berry
Starpharma Holdings Ltd
+61 3 8532 2702
Copyright © PR Newswire Association LLC.If you have a comment, please Contact us.
Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
|Related News Press|
Nanoparticles simplify DNA identification and quantification November 27th, 2015
Scientists 'see' detailed make-up of deadly toxin for the first time: Exciting advance provides hope for developing novel potential method of treating pneumococcal diseases such as bacterial pneumonia, meningitis and septicaemia November 25th, 2015
CEA-Leti to Share Insights into Post-7-nanometer Technologies At Workshop Prior to IEDM in Washington, D.C.: Research Includes CMOS Device Architectures, New Materials and Computing System Paradigms December 1st, 2015
Electric fields remove nanoparticles from blood with ease November 24th, 2015
Breakthrough allows tracking of single molecules in 3-D with nanoscale accuracy:New method builds on Nobel Prize-winning technique, with exciting implications for understanding the inner workings of cells and neurons November 23rd, 2015